Real-world use of sorafenib for advanced renal cell carcinoma patients with cardiovascular disease: nationwide survey in Japan.
In: Expert Review of Anticancer Therapy, Jg. 20 (2020-07-01), Heft 7, S. 615-623
academicJournal
Zugriff:
Objectives: To assess whether the clinical outcome of advanced/metastatic renal cell carcinoma (mRCC) treated with sorafenib, in real-world conditions, differs in patients with cardiovascular disease (CVD). Methods: mRCC patients (n = 2256 before matching) were matched by propensity score into CVD (n = 560) and non-CVD groups (n = 560), followed by safety and effectiveness analyzes. Results: After matching, patients' features used for matching were balanced between the CVD and non-CVD groups, except for age (p = 0.0049). Renal comorbidity occurred more frequently in the CVD group. Exposure to sorafenib and objective response rate (25.4% [CVD], 28.5% [non-CVD]) were comparable in both groups. Median progression-free survival (PFS; 7.1 months, 95% CI: 6.4-8.6 [CVD]; 6.7 months, 6.3-8.3 [non-CVD]), and hazard ratios for PFS (0.954, 0.821-1.108) and overall survival (0.889, 0.683-1.156), were similar in the matched population. The incidences of adverse drug reactions (ADR, ≥10%) were generally similar between groups, although hypertension (42.1% vs 34.5%), diarrhea (26.3% vs 19.6%), decreased appetite (11.3% vs 7.5%), and non-serious and serious renal failure/dysfunction (3.6% vs 1.4% and 1.8% vs 0.4%), occurred more frequently in the CVD group. Conclusion: This analyzes suggests that sorafenib has clinical benefit for mRCC patients regardless of baseline CVD. Serious ADRs increased for renal dysfunction. Clinical Trial Registration: www.clinicaltrials.gov identifier is NCT01411423. [ABSTRACT FROM AUTHOR]
Copyright of Expert Review of Anticancer Therapy is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Real-world use of sorafenib for advanced renal cell carcinoma patients with cardiovascular disease: nationwide survey in Japan.
|
---|---|
Autor/in / Beteiligte Person: | Inamoto, Teruo ; Azuma, Haruhito ; Tatsugami, Katsunori ; Oya, Mototsugu ; Adachi, Masatoshi ; Okayama, Yutaka ; Sunaya, Toshiyuki ; Akaza, Hideyuki |
Zeitschrift: | Expert Review of Anticancer Therapy, Jg. 20 (2020-07-01), Heft 7, S. 615-623 |
Veröffentlichung: | 2020 |
Medientyp: | academicJournal |
ISSN: | 1473-7140 (print) |
DOI: | 10.1080/14737140.2020.1773805 |
Schlagwort: |
|
Sonstiges: |
|